Wegovy and Ozempic: Same Drug, Different Indications and Doses
Wegovy and Ozempic both contain the identical active ingredient—semaglutide—but are FDA-approved for different purposes: Wegovy is specifically approved for chronic weight management at higher doses (up to 2.4 mg weekly), while Ozempic is approved for type 2 diabetes management at lower doses (up to 1 mg weekly). 1, 2
Key Differences
FDA-Approved Indications
- Ozempic: Approved for improving glycemic control in adults with type 2 diabetes mellitus 2
- Wegovy: Approved for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity 1
Dosing Regimens
Both are administered as once-weekly subcutaneous injections, but the maximum doses differ:
- Ozempic: Doses up to 1.0 mg weekly for diabetes management 2
- Wegovy: Doses escalate from 0.25 mg to a maintenance dose of 2.4 mg weekly for weight loss 1
The dose escalation for Wegovy occurs every 4 weeks: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg 1
Clinical Efficacy
For Weight Loss: Wegovy at 2.4 mg weekly produces substantial weight reduction. In the STEP 1 trial, patients achieved mean weight loss of 14.9% at 68 weeks (versus 2.4% with placebo) 3. This degree of weight loss was previously only achievable with bariatric surgery 4.
For Cardiovascular Outcomes: The SELECT trial demonstrated that Wegovy 2.4 mg reduced major adverse cardiovascular events (cardiovascular death, nonfatal MI, or nonfatal stroke) by 20% in patients with established cardiovascular disease and BMI ≥27 without diabetes 3, 4.
Pharmacology
Both formulations contain the same molecular structure (C187H291N45O59, molecular weight 4113.58 g/mol) with 94% sequence homology to human GLP-1 1, 2. The mechanism involves:
- Appetite suppression through central nervous system GLP-1 receptors
- Delayed gastric emptying
- Glucose-dependent insulin secretion (relevant for diabetes management)
- Reduced glucagon secretion
Important Clinical Considerations
Common Pitfall: Using Ozempic off-label for weight loss has become widespread due to Wegovy shortages and cost differences 5. However, the 1.0 mg maximum dose of Ozempic provides suboptimal weight loss compared to Wegovy's 2.4 mg dose.
Adverse Events: Both formulations share the same side effect profile—predominantly gastrointestinal (nausea, vomiting, diarrhea)—which are dose-dependent and managed through gradual titration 4. Rare but serious risks include pancreatitis and gallbladder disorders 4.
Long-term Use Required: Weight regain occurs after discontinuation. In STEP 4, patients who stopped semaglutide after 20 weeks regained 6.9% of lost weight over 48 weeks 3. Lifelong treatment is typically necessary for sustained weight management 3.
Renal and Hepatic Impairment: No dose adjustments are required for either formulation in patients with renal or hepatic impairment 1, 2.
Bottom Line for Clinical Practice
If treating obesity or overweight with comorbidities, prescribe Wegovy at the full 2.4 mg weekly dose to achieve clinically meaningful weight loss and cardiovascular risk reduction 3, 1. If treating type 2 diabetes where weight loss is a secondary benefit, Ozempic up to 1.0 mg weekly is appropriate 2. Using Ozempic off-label for weight management delivers inferior results compared to the FDA-approved Wegovy dosing regimen.